[Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma]

Mathilde Chanut; Charles Herbaux

doi:10.1016/j.bulcan.2023.06.010

[Lisocabtagene maraleucel CAR-T cells - second line treatment in patients with relapsed or refractory large B cell lymphoma]

Bull Cancer. 2023 Oct;110(10):986-988. doi: 10.1016/j.bulcan.2023.06.010. Epub 2023 Sep 1.

[Article in French]

Authors

Mathilde Chanut¹, Charles Herbaux²

Affiliations

¹ Hôpital Saint-Louis, service d'hématologie-oncologie, 1, avenue Claude-Vellefaux, 75010 Paris, France. Electronic address: mathilde.chanut@aphp.fr.
² Hôpital Saint-Eloi, service d'hématologie clinique, 80, avenue Augustin-Fliche, 34090 Montpellier, France.

PMID: 37661551
DOI: 10.1016/j.bulcan.2023.06.010

No abstract available

Keywords: CAR-T cells; Cellules CAR-T; Large diffuse B cells lymphoma; Lymphome B diffus à grandes cellules; Lymphome primitif du médiastin; Primitive B mediastinal lymphoma; Rechute; Refractory; Relapse; Réfractaire.

Publication types

Letter

MeSH terms

Humans
Immunotherapy, Adoptive / adverse effects
Lymphoma, Large B-Cell, Diffuse* / pathology
Lymphoma, Large B-Cell, Diffuse* / therapy
T-Lymphocytes / pathology